CASI Pharmaceuticals in-licenses rights to novel anti-CD38 monoclonal antibody program from Black Belt Therapeutics

Image: Preclinical data demonstrate TSK011010 to have enhanced activity against a broad array of malignancies. Photo: courtesy of cuteimage / FreeDigitalPhotos.net.